Subcutaneous Pertuzumab/Trastuzumab/Hyaluronidase-zzxf Approved for HER2-Positive Breast Cancer

The FDA has approved a subcutaneous injection of pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo®, Genentech, Inc.) for adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This fixed-dose combination treatment is approved in combination with chemotherapy as neoadjuvant therapy for patients who have locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive) disease; as adjuvant treatment for patients with HER2-positive ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.